Category Archives: ADCETRIS

Clay Seigall

Since 1988, Seattle Genetics has held court high atop the hill at Bothell’s Cascade Business Park, overseeing the study, creation, and packaging of human antibodies transformed into pharmaceuticals to fight cancer. Clay Seigall – president/co-founder/chairman/CEO of Seattle Genetics is the reason the company is on the fast track to becoming a monumental force on it’s own, refusing to sell out to a larger corporation. Seigall has proven that he will never be content with simply re-manufacturing already existing cancer-fighting drugs; he is focused on personally overseeing all of the details related to the marketing of more updated drugs worldwide. Siegall has now opened a Switzerland location for Seattle Genetics so that the company will be able to oversee it’s own international marketing ventures.

In February, Clay Siegall put into place a plan to invest $2 billion in the acquisition of international rights to commercialize a newly-developed cancer-fighting drug developed by Immunomedics, a New Jersey-based biopharmaceutical company. This move, though ultimately unsuccessful, proved to the world Seattle Genetics’ dedication to the advancement of making oncology drugs available on the global markets.

In the second half of 2016, Seattle Genetics recorded sales of approximately $418 million, an increase of nearly 50% since 2014. Stock prices have more than tripled in the past 5 years. Future projections indicate further increases in both stock prices and company revenue are fully expected for Seattle Genetics under Siegall’s guidance.

Clay Seigall holds a B.S. in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. He held prestigious positions with the National Cancer Institute and the National Institutes of Health from 1988-1991, and with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991-1997. Currently he sits on the Alder Biopharmaceuticals Board of Directors. Alder Biopharmaceuticals is a private biotechnology company. He holds an impressive 15 patents and is the esteemed author of over 70 publications.

Seigall’s inspiration for Seattle Genetics was a result of his father’s death from cancer when Clay was 24 years old. Having watched his father struggle with the disease for 7 years, he became acutely aware of the lack of truly effective cancer-fighting medications and methods that were available, and he was determined to improve these tools to combat cancer the world over. He dedicated his education and his life’s work to developing more comprehensive methods of early detection of various cancers as well as the study and development of powerful cancer-fighting medications and treatments. His vision is to make these tools available worldwide to battle cancer everywhere.